ChiCTR1900026499.

Study name	Albumin‐bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple‐negative breast cancer: a multicenter randomized controlled phase IV clinical trial
Methods	Accrual: not yet recruiting Accrual target: 110 Multicentre, phase 4 RCT Trial is being conducted in China Blinding: participants, investigators, outcome assessors
Participants	People with stage II–III breast cancer Adjuvant or neoadjuvant: neoadjuvant
Interventions	Arm 1: intervention: paclitaxel and carboplatin (no further details provided) Arm 2: comparator: epirubicin and docetaxel (no further details provided)
Outcomes	Primary Pathological complete remission rate Secondary Breast‐conserving rate Incidence of osteoporosis Incidence of bone‐related events Incidence of other distant organ metastasis related events Disease‐free survival Overall survival Adverse events
Starting date	Planned start date: 1 December 2019 Estimated completion date: 31 May 2026
Contact information	Contact: Caigang Liu (liucg@sj‐hospital.org)
Notes	Trial registration link: www.chictr.org.cn/showprojEN.html?proj=44204 Trial sponsor: Shengjing Hospital of China Medical University Funding considerations: self‐financed